4//SEC Filing
Pinto Alexis 4
Accession 0001725160-21-000206
CIK 0001725160other
Filed
Oct 26, 8:00 PM ET
Accepted
Oct 27, 8:13 PM ET
Size
14.5 KB
Accession
0001725160-21-000206
Insider Transaction Report
Form 4
Pinto Alexis
Chief Legal Officer
Transactions
- Sale
Common Stock
2021-10-25$76.10/sh−1,800$136,973→ 34,726 total - Sale
Common Stock
2021-10-25$77.27/sh−8,098$625,731→ 26,628 total - Sale
Common Stock
2021-10-25$78.85/sh−300$23,655→ 6,526 total - Exercise/Conversion
Common Stock
2021-10-25$34.40/sh+30,000$1,032,000→ 36,526 total - Sale
Common Stock
2021-10-25$78.05/sh−19,802$1,545,643→ 6,826 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-10-25−30,000→ 245,000 totalExercise: $34.40Exp: 2030-08-30→ Common Stock (30,000 underlying)
Footnotes (6)
- [F1]The stock option exercise and sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021.
- [F2]Includes 276 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on September 30, 2021.
- [F3]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $75.57 to $76.53. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $76.59 to $77.58. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $77.59 to $78.44. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The options vest and become exercisable as to 25% of the total number of shares underlying the option on August 31, 2021 and as to the remaining 75% in 36 substantially equal monthly installments thereafter.
Documents
Issuer
Zentalis Pharmaceuticals, Inc.
CIK 0001725160
Entity typeother
Related Parties
1- filerCIK 0001819302
Filing Metadata
- Form type
- 4
- Filed
- Oct 26, 8:00 PM ET
- Accepted
- Oct 27, 8:13 PM ET
- Size
- 14.5 KB